Registration is now open for CSI’s Alternative Assessment Program
CSI offers the Alternative Assessment Program for clients who are performing and billing for the interpretation component of FISH cases. This program is meant to assist clients in satisfying the necessary College of American Pathologists (CAP) Checklist Requirements for the twice-yearly performance of alternative assessments for the interpretation-only component of FISH cases. (For more information on the CAP Checklist Requirements, please visit www.cap.org).
Alternative Assessment Registration Form
Immunotherapy available for tumors identified as dMMR or MSI-H
Patients with unresectable or metastatic solid tumors identified as mismatch repair deficient (dMMR by IHC) or microsatellite instability-high (MSI-H by PCR) who have progressed following other treatments are now eligible for Keytruda®(pembrolizumab) immunotherapy. A recent FDA accelerated approval based on these biomarkers permits the use of Keytruda® immunotherapy in qualified patients, regardless of solid tumor site. For additional details on these biomarker assays, click here.
ASCO Guidelines Update for Stage IV NSCLC Patients